DICLO-FLAM BLACKCURRANT


Dispersible tablets 9s
scheduling status
S2
registration number
37/3.1/0607
What DICLO-FLAM BLACKCURRANT is and what it is used for
DICLO-FLAM BLACKCURRANT is indicated for: • Emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days.
dosage
Adults As a general recommendation, the dose should be individually adjusted. Use the lowest effective dose for the shortest possible duration of treatment. Dissolve one tablet in water three times a day for acute gout attacks. The recommended initial daily dose is 100 mg to 150 mg. In milder cases 50 mg to 100 mg daily is usually sufficient. The total daily dosage should generally be divided into 2 to 3 separate doses. The maximum daily dose is 150 mg for a maximum treatment period of 3 days (three DICLO-FLAM BLACKCURRANT dispersible tablets in divided doses). Adolescents For adolescents aged 14 years or over, a daily dose of 50 mg to 100 mg is usually sufficient. The total daily dose should generally be divided in 2 to 3 doses. The maximum daily dose of 150 mg should not be exceeded.
how to take
Oral administration. DICLO-FLAM BLACKCURRANT tablets should preferably be taken on an empty stomach. DICLO-FLAM BLACKCURRANT tablets should be dropped into a glass of water and the liquid stirred to aid dispersion before swallowing. Since a proportion of the active medicine may remain in the glass after swallowing, it is advisable to rinse the glass with a small amount of water and to swallow again. The tablets must not be divided or chewed.
What DICLO-FLAM BLACKCURRANT contains
Each dispersible tablet of DICLO-FLAM BLACKCURRANT contains 46,5 mg of diclofenac free acid, equivalent to 50,0 mg of diclofenac sodium.
other ingredients
Blackcurrant flavour, croscarmellose sodium, glycerol distearate, microcrystalline cellulose, purified talc, saccharin sodium, sodium starch glycolate. Contains sweetener: Saccharin sodium 0,26 mg Sugar free.
Therapeutic classification
M01AB05 (A 3.1 Antirheumatics (anti-inflammatory agents)).
© 2026 SAHPRA. ALL RIGHTS RESERVED